IMR Press / CEOG / Volume 38 / Issue 4 / pii/1630543035820-969533704

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research
Serum osteoprotegerin correlates with age and bone mass in postmenopausal, but not in fertile age women
Show Less
1 Fondazione IRCCS SDN, Naples (Italy)
Clin. Exp. Obstet. Gynecol. 2011, 38(4), 355–359;
Published: 10 December 2011
Abstract

Purpose of investigation: Osteoprotegerin (OPG) and receptor activator of nuclear factor κB ligand (RANKL) are bone turnover modulators expressed by osteoblasts. The aim of this study was to assess the relationship between the circulating OPG/RANKL system, age and bone mass, in fertile age and postmenopausal women. Methods: In this cross-sectional observational study on 48patients (fertile age, n = 22; postmenopause, n = 26), we investigated the correlation between serum OPG and RANKL, age and bone mineral density (BMD). Serum concentrations of OPG and RANKL were determined by enzyme-linked immunosorbent assay(ELISA); estimate BMD evaluation was performed with heel quantitative ulrasonometry (QUS). Results: Serum OPG significantly increased (p=0.003) and serum RANKL significantly decreased (p = 0.002), in the postmenopausal group compared to fertile agewomen. A significant correlation of serum OPG with age (rs = 0.39, p = 0.047) and BMD (rs = 0.45, p =0.023) in postmenopausalwomen, and between RANKL and BMD (rs = 0.48, p = 0.024) in fertile age was found. Conclusion: These data demonstrate in vivo that the OPG/RANKL system is significantly associated with menopausal status and could play a role in postmenopausal osteoporosis.
Keywords
Osteoprotegerin
RANKL
Menopause
Osteoporosis
Share
Back to top